B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial
Maja Jahnmatz, Sylvie Amu, Margaretha Ljungman, Lena Wehlin, Francesca Chiodi, Nathalie Mielcarek, Camille Locht, Rigmor Thorstensson, Maja Jahnmatz, Sylvie Amu, Margaretha Ljungman, Lena Wehlin, Francesca Chiodi, Nathalie Mielcarek, Camille Locht, Rigmor Thorstensson
Abstract
Despite high vaccination coverage, pertussis is still a global concern in infant morbidity and mortality, and improved pertussis vaccines are needed. A live attenuated Bordetella pertussis strain, named BPZE1, was designed as an intranasal vaccine candidate and has recently been tested in man in a phase I clinical trial. Here, we report the evaluation of the B-cell responses after vaccination with BPZE1. Forty-eight healthy males with no previous pertussis-vaccination were randomized into one of three dose-escalating groups or into a placebo group. Plasma blast- and memory B-cell responses were evaluated by ELISpot against three different pertussis antigens: pertussis toxin, filamentous haemagglutinin and pertactin. Seven out of the 36 subjects who had received the vaccine were colonized by BPZE1, and significant increases in the memory B-cell response were detected against all three tested antigens in the culture-positive subjects between days 0 and 28 post-vaccination. The culture-positive subjects also mounted a significant increase in the filamentous haemagglutinin-specific plasma blast response between days 7 and 14 post-vaccination. No response could be detected in the culture-negatives or in the placebo group post-vaccination. These data show that BPZE1 is immunogenic in humans and is therefore a promising candidate for a novel pertussis vaccine. This trial is registered at ClinicalTrials.gov (NCT01188512).
Keywords: B cells; BPZE1; Live attenuated nasal vaccine; Novel human vaccine; Pertussis; Phase I clinical trial.
Copyright © 2014. Published by Elsevier Ltd.
Source: PubMed